Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a pharmacovigilance study based on FAERS
This study provides valuable safety data on the real-world application of anifrolumab, confirming known AEs and revealing additional potential risks. The findings offer critical safety information for clinicians prescribing anifrolumab for the treatment of SLE, aiding in the optimization of patient management and treatment decision-making.
Authors
- Y F Cheng
- Jun Niu (ORCID: https://orcid.org/0000-0001-7371-917X)
- Jingyi Ma (ORCID: https://orcid.org/0000-0003-2978-1413)
Institutions
- General Hospital of Shenyang Military Region (CN)
- China Medical University (CN)
Publication Details
- Journal
- BMC Rheumatology
- Published
- 2025-07-21
- DOI
- https://doi.org/10.1186/s41927-025-00545-4
- Citations
- 2
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Department of Science and Technology of Liaoning Province